ONC · BeOne Medicines Ltd. · Executive Compensation
$365.94
+0.67 (+0.18%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$40.82B
Shares
113.12M
Volume · Sep 30
328.88K
Avg daily vol (3M)
388.06K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Margaret Dugan | member of the Compensation Committee of the Board of Directors | Appointed | 2026-06-11 |
| John V. Oyler | Chairman of the Board of Directors | Appointed | 2026-06-11 |
| Elizabeth F. Mooney | director | Appointed | 2026-06-11 |
| Charles L. Sawyers | director | Appointed | 2026-06-11 |
| Felix J. Baker | director | Appointed | 2026-06-11 |
| Dr. Lai Wang | President, Global Head of Research and Development | Appointed | 2025-12-18 |
| Shalini Sharp | Class III director | Appointed | 2024-09-26 |
| Julia Wang | CFO | Resigned | 2024-07-18 |
| Aaron Rosenberg | Chief Financial Officer | Appointed | 2024-07-18 |
| Titus Ball | principal accounting officer | Appointed | 2024-03-20 |
| Olivier Brandicourt | Class II director | Appointed | 2024-01-23 |
| Thomas Malley | member of the Board of Directors | Resigned | 2024-01-23 |
Key facts
CIK
1651308
CUSIP
07725L102
13F (30d)
10 filings
8 filers
Visit website
Investor relations